Discover
ABVC
ABVC BioPharma, Inc.
1.77
2 x 1.27
2 x 1.97
bid
ask
+
0.19
12.03%
2 @ 04:00 PM
1.76 -0.01 (0.67%)
| Ytd | -16.90% | |
| 1y | -26.86% |
1.54
day range
1.83
0.88
52 week range
5.48
| Open | 1.56 | Prev Close | 1.58 | Low | 1.54 | High | 1.83 | Mkt Cap | 46.02M |
| Vol | 276.75K | Avg Vol | 134.31K | EPS | -0.39 | P/E | N/A | Forward P/E | -1.16 |
| Beta | 0.82 | Short Ratio | 0.70 | Inst. Own | 3.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.24 | 200-d Avg | 1.93 | 1yr Est | 2.02 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | 0 | -0.02 | N/A | N/A |
| 2024-08-14 | 2024-06 | 0 | -0.09 | N/A | N/A |
| 2024-05-17 | 2024-03 | 0 | -0.4 | N/A | N/A |
| 2024-03-13 | 2023-12 | 0 | -0.35 | N/A | N/A |
| 2023-11-15 | 2023-09 | 0 | -0.82 | N/A | N/A |
| 2023-08-14 | 2023-06 | 0 | -0.68 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Geode Capital Management, LLC | 71.61K | 36.52K | 0.55% |
| 2024-09-29 | Vanguard Group Inc | 46.95K | 23.94K | 0.36% |
| 2024-09-29 | Avantax Planning Partners, Inc. | 39.00K | 19.89K | 0.30% |
| 2024-09-29 | Xtx Topco Ltd | 23.41K | 11.94K | 0.18% |
| 2024-09-29 | Northern Trust Corporation | 19.14K | 9.76K | 0.15% |
| 2024-09-29 | State Street Corporation | 12.90K | 6.58K | 0.10% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 52.78K | 26.92K | 0.41% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 46.95K | 23.94K | 0.36% |
| 2024-10-30 | Fidelity Total Market Index Fund | 14.39K | 7.34K | 0.11% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 12.46K | 6.36K | 0.10% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2023-07-25 |
| 1 : 18 | 2019-05-08 |
| 3 : 1 | 2016-04-11 |
| 1 : 5000 | 2015-08-13 |
| 1 : 5 | 2011-02-18 |
| 1573 : 1000 | 2007-06-19 |